Skip to main content

Peer Review reports

From: A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

Original Submission
1 Oct 2022 Submitted Original manuscript
28 Nov 2022 Author responded Author comments - Martina Eriksen
Resubmission - Version 2
28 Nov 2022 Submitted Manuscript version 2
Publishing
6 Dec 2022 Editorially accepted
16 Dec 2022 Article published 10.1186/s12885-022-10420-x

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us